Pediatrix Medical Q1 GAAP EPS $0.05 vs $0.17 YoY; revenue up slightly to $495M

Pediatrix Medical Group, Inc.

2024-Q1 EPS reported $0.05 revenue$495,101,000

Net revenue $495M vs $491M YoY; same-unit revenue up 2.3%.
Net income $4M down from $14.2M; GAAP EPS $0.05 vs $0.17.
Adjusted EPS $0.20 vs $0.23; Adjusted EBITDA $37M vs $40.1M.
FY 2024 Adjusted EBITDA guidance reaffirmed $200M-$220M.
Cash used in ops $122.6M; total debt $705M at quarter end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Pediatrix Medical Group, Inc. reported the three months ended March 31, 2024 results: revenue $495.1 million, net income $4.0 million, EPS $0.05 per diluted share. Guidance reaffirmed.

Period: the three months ended March 31, 2024
Revenue: $495.1 million
Net income: $4.0 million
EPS: $0.05 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: • Net revenue of $495 million; • Net income of $4 million; and • Adjusted EBITDA of $37 million. “Our first quarter operating results were in line with our expectations,” said James D. Swift, M.D., Chief

View on SEC.gov

Browse all earnings releases →

Pediatrix Medical Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053917

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.